Navigation Links
Misonix Announces New Distribution Agreement for Peru
Date:1/11/2010

FARMINGDALE, N.Y., Jan. 11 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with ROCA, S.A.C., based in Lima, Peru, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) Ultrasonic Bone Cutter, and the SonicOne® Ultrasonic Wound Debrider. The agreement provides ROCA with the rights to sell in Peru, and includes minimum purchase requirements.

ROCA, well known in Peru as an aggressive competitor, has built a reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis on Neuro and General Surgery.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is quite pleased with the addition of ROCA to our rapidly expanding roster of Latin American specialty distributors. ROCA's reputation as a high-profile distributor of advanced medical equipment in Peru is well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Their commitment to quality and service, as well as their success in introducing high tech medical devices, was appealing to Misonix. We are particularly pleased that they will be selling three of our key products through their well established distribution network."

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.


    Investor Relations Contact:
    Kevin McGrath/Cameron Associates, Inc.
    212-245-4577
    Kevin@cameronassoc.com

SOURCE Misonix, Inc.

RELATED LINKS
http://www.misonix.com

'/>"/>

SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
2. Misonix Reports First Quarter Fiscal 2010 Financial Results
3. Misonix Announces New Distribution Agreement for Argentina
4. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
5. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
7. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
8. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
9. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
10. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
11. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
Breaking Medicine News(10 mins):